Researchers at Johns Hopkins have established a human cell-based system for studying sickle cell anemia by reprogramming somatic cells to an embryonic stem cell like state. Researchers at Johns Hopkins have established a human cell-based system for studying sickle cell anemia by reprogramming somatic cells to an embryonic stem cell like state. Publishing online in Stem Cells on May 29, the team describes a faster and more efficient method of reprogramming cells that might speed the development of stem cell therapies.
“We hope our new cell lines can open the doors for researchers who study diseases like sickle cell anemia that are limited by the lack of good experimental models,” says Linzhao Cheng, Ph.D., an associate professor of gynecology and obstetrics, medicine and oncology and a member of the Johns Hopkins Institute for Cell Engineering.
The research team first sought to improve previously established methods for reprogramming of adult cells into so-called induced pluripotent stem (iPS) cells, which look and behave similarly to embryonic stem cells and can differentiate into many different cell types. After testing several different genes, they were able to improve reprogramming efficiency by adding a viral protein known as SV40 large T antigen.
Using both fetal and adult human skin cells, the researchers introduced the four genes previously reported sufficient for cell reprogramming and compared the efficiency of reprogramming in the presence or absence of large T antigen. Without large T, cells form embryonic stem cell-like clusters in three to four weeks. With large T, the cells started looking like embryonic stem cells in just 12 to 14 days.
“Not only did T speed up reprogramming, we also found that it increases the total number of reprogrammed cells, which is great because often in reprogramming, not all cells go all the way,” says Cheng, who explains that rigorous follow-up tests are required to determine if the reprogrammed cells really behave like pluripotent embryonic stem cells. “Many of them look right but they’re probably just half cooked-like a boiled egg, you just can’t tell the difference by looking at the outside,” he says.
Having established a faster, more efficient method, the team then reprogrammed human cells that contain the mutation associated with sickle cell anemia. Embryonic stem cell-like clusters were visible 14 days after they initiated reprogramming and from these clusters the researchers established three different cell lines that both look and behave like human embryonic stem cells.
“One challenge to studying blood diseases like sickle cell anemia is that blood stem cells can’t be kept alive for very long in the lab, so researchers need to keep returning to patients for more cells to study,” says Cheng. “Having these new cell lines available might enable some bigger projects, like screening for potential drugs.”
Source: Johns Hopkins Medical Institutions
Related stories:
Mayo researchers explore issues related to multiple myeloma treatment
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. Unfortunately, some of the most effective therapies also have toxic side effects that can pose serious health risks and reduce quality of life. In the October issue of
Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments.
Scientists identify a molecule that coordinates the movement of cells
Even cells commute. To get from their birthplace to their work site, they sequentially attach to and detach from an elaborate track of exceptionally strong proteins known as the extracellular matrix. Now, in research to appear in the October 3 issue of
Cell, scientists at the Howard Hughes Medical Institute and Rockefeller University show that a molecule, called ACF7, helps regulate and power this movement from the inside - findings that could have implications for understanding how cancer cells metastasize.
Biochemists devise method for bypassing aluminum toxicity effects in plants
(PhysOrg.com) -- Aluminum toxicity, a global agricultural problem, halts root growth in plants, severely limiting agricultural productivity for more than half of the world's arable land.
The role of stem cells in renewing the cornea
A group of researchers in Switzerland has published a study appearing in the Oct 1 advance online edition of the Journal
Nature that shows how the cornea uses stem cells to repair itself.
Cells that Avoid Suicide May Become Cancerous
(PhysOrg.com) -- When a cell's chromosomes lose their ends, the cell usually kills itself to stem the genetic damage. But University of Utah biologists discovered how those cells can evade suicide and start down the path to cancer.
Reversible 3-D cell culture gel invented
Singapore's Institute of Bioengineering and Nanotechnology (IBN), which celebrates its fifth anniversary this year, has invented a unique user-friendly gel that can liquefy on demand, with the potential to revolutionize three-dimensional (3D) cell culture for medical research.
Important new step toward producing stem cells for human treatment
(PhysOrg.com) -- A team of Harvard Stem Cell Institute (HSCI) scientists has taken an important step toward producing induced pluripotent stem (iPS) cells that are safe to transplant into patients to treat diseases.
Resetting immune system in bid to beat scleroderma
(AP) -- First Bari Martz's fingers turned blue. Then she started gasping for breath, and her joints stiffened so that she couldn't even open her hands. Doctors diagnosed scleroderma, part of an insidious family of diseases where the immune system attacks a patient's own body, sometimes enough to kill.